# A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain

> **NCT01767090** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 912 (actual)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** ASP1707
- **DRUG:** Placebo
- **DRUG:** Leuprorelin acetate

## Key facts

- **NCT ID:** NCT01767090
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-04
- **Primary completion:** 2015-05-13
- **Final completion:** 2015-07-30
- **Target enrollment:** 912 (ACTUAL)
- **Last updated:** 2024-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01767090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01767090, "A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01767090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*